US 12,220,451 B2
Cell-based vaccine compositions and methods of use
Michael D. Gunn, Durham, NC (US); and Min-Nung Huang, Durham, NC (US)
Assigned to Duke University, Durham, NC (US)
Appl. No. 16/075,830
Filed by Duke University, Durham, NC (US)
PCT Filed Feb. 3, 2017, PCT No. PCT/US2017/016362
§ 371(c)(1), (2) Date Aug. 6, 2018,
PCT Pub. No. WO2017/136633, PCT Pub. Date Aug. 10, 2017.
Claims priority of provisional application 62/291,086, filed on Feb. 4, 2016.
Prior Publication US 2019/0381158 A1, Dec. 19, 2019
Int. Cl. A61K 39/00 (2006.01); A61K 35/15 (2015.01); A61K 45/06 (2006.01)
CPC A61K 39/001156 (2018.08) [A61K 35/15 (2013.01); A61K 2039/5158 (2013.01); A61K 2039/876 (2018.08); A61K 45/06 (2013.01)] 17 Claims
 
1. A method of generating a cellular vaccine composition comprising:
(a) isolating a population of cells comprising monocyte cells from a sample from a subject using negative selection for CD14, wherein less than 5% of the cells in the population of cells are dendritic cells, and wherein at least 50% of the cells in the population of cells are monocytes, wherein the monocytes are CD14+ and CCR7−;
(b) contacting the population of cells from step (a) with at least one antigenic polypeptide or at least one polynucleotide encoding the at least one antigenic polypeptide, wherein the antigenic polypeptide comprises an isocitrate dehydrogenase 1 polypeptide or a tyrosinase-related protein 2 polypeptide; and
(c) harvesting the population of cells of step (b), thereby generating a harvested population of cells, wherein less than 5% of the cells in the harvested population of cells are dendritic cells, wherein at least 70% of the cells in the harvested population of cells are monocytes, wherein the monocytes are CD14+, CD1−, CD83−, and CCR7−, suspending the population of cells in a pharmaceutically acceptable carrier, wherein the cells are suspended in a single dose formulation comprising a therapeutically effective amount, wherein the therapeutically effective amount is about 10-fold less than a therapeutically effective amount of antigen loaded lymphocytes, whole blood cells, or total splenocytes, to prepare the cellular vaccine composition.